Forte Biosciences (FBRX) surged approximately 266% over the past 30 days, climbing from around $20.92 to $76.56 as of August 4, 2026. The primary catalyst was positive Phase 1b vitiligo data for lead candidate FB102, which sent shares soaring 78% in a single session on July 9.

Ibotta (IBTA) shares climbed approximately 13.2% over the last 30 days, propelled by a massive single-day surge following stronger-than-expected Q2 2026 earnings. The company reported revenue of $88.91 million, returning to year-over-year growth for the first time since Q1 2025, and delivered adjusted EBITDA of $16.5 million — 58% above the midpoint of its own guidance.

CG Oncology (CGON) is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. The stock has traded in a relatively contained range over the past 30 days, with a modest gain of approximately 3%, reflecting a period of consolidation following stronger year-to-date gains.

Net profit surged 75.6% to 1.48 trillion yen ($9.4 billion) in Q1 FY2027, handily beating the consensus estimate of approximately 978 billion yen, though the jump was driven largely by currency gains and non-operating income rather than core automotive performance. Operating income declined 8.8% to 1.06 trillion yen, marking the fifth consecutive quarter of year-over-year operating profit contraction. The operating margin narrowed to 7.9% from 9.5% a year earlier.

Arista Networks delivered its first-ever $3 billion revenue quarter , reporting Q2 2026 revenue of $3.036 billion, up 37.7% year-over-year. Non-GAAP diluted earnings per share (EPS) came in at $1.02 , handily beating the consensus analyst estimate of approximately $0.88 to $0.89.

Revenue exceeded expectations: Merck posted second-quarter 2026 sales of $16.6 billion, up 5% year over year and ahead of the $16.41 billion consensus estimate. Non-GAAP EPS beat convincingly: The company reported an adjusted loss of $0.13 per share, significantly better than the $0.27 loss Wall Street had forecast.

HSBC reported second-quarter profit before tax of $10.1 billion , a 60% year-over-year surge that comfortably beat the consensus estimate of $9.51 billion. Revenue climbed to $19.1 billion , exceeding analyst forecasts of $18.51 billion, driven by strong wealth management fees and higher net interest income.

Caterpillar posted its first $20 billion quarter in company history, with sales and revenues reaching $20.5 billion, up 24% year-over-year and handily beating Wall Street's consensus estimate of approximately $19.3 billion. Adjusted earnings per share surged 73% to $8.17, far exceeding the analyst consensus of roughly $6.19–$6.25 per share, while GAAP (Generally Accepted Accounting Principles) EPS climbed to $7.77 from $4.62 a year ago.

Revenue reached a record $11.54 billion , up 50% year-over-year and ahead of the $11.28 billion consensus estimate. Non-GAAP earnings per share came in at $1.66 , exceeding Wall Street's $1.62 forecast and reflecting an 82% comparable increase from the prior year.

Xenon Pharmaceuticals shares traded at $64.01 as of early August 2026, reflecting a modest gain of approximately 5.7% over the trailing 30-day period. The company's lead asset, azetukalner, delivered highly positive Phase 3 X-TOLE2 data in focal onset seizures and management expects to submit a New Drug Application to the FDA in the third quarter of 2026.

Scholar Rock (SRRK) shares fell approximately 13.7% over the last 30 days, declining from $55.36 on July 6, 2026, to $47.79 as of August 4, 2026. The primary catalyst behind the sell-off was an announcement on July 20 that the European Medicines Agency's (EMA) CHMP opinion on apitegromab hinges on the FDA's classification of the Catalent Indiana manufacturing facility, introducing fresh regulatory uncertainty.

MOVE shares closed at $13.73 on Tuesday, up +27.60% from the prior session's close of $10.76, after spiking as much as +112% in pre-market trading and opening at $18.78 before pulling back during the regular session. The primary catalyst: Corvex announced a multi-year agreement to supply clusters of NVIDIA Blackwell GPUs with Quantum-2 InfiniBand networking to a leading, unnamed AI company, expanding an existing customer commitment.

BRKR closed at $50.30, plunging -21.79% during the regular trading session following the release of Q2 2026 earnings. The primary catalyst was a revenue miss: Q2 revenue of $838.5M fell short of the $853.39M analyst consensus, and the company lowered its full-year FY2026 revenue guidance midpoint to $3.56B from $3.59B, also below Street estimates.

CERT closed at $7.80 on Tuesday, down -4.65% from $8.18, after an extreme intraday swing from a low of $6.33 to a high of $7.83 on heavy volume of 10.8M shares. The move followed a steep premarket gap down of nearly -19% after Q2 2026 earnings were released before the open, with the stock recovering substantially during the regular session.

REZI closed at $26.17 on Tuesday, plunging -27.77% ($10.06) from its previous close of $36.23, with the entire move occurring during regular trading hours. The decline is a mechanical price adjustment following the completion of the ADI Global Distribution spin-off, with ADI beginning independent trading on the NYSE under ticker ADIG on August 4.

Element Solutions shares have declined approximately 8% over the past 30 days as the initial merger premium from the Solstice Advanced Materials acquisition announcement continues to erode. The $14.5 billion cash-and-stock buyout, announced July 6, valued ESI at roughly $50.10 per share — a level the stock has since drifted significantly below amid shareholder dissatisfaction on both sides.

AHCO plunged -38.13% during Tuesday's regular session, closing at $6.70 after reporting Q2 2026 results that severely missed expectations across all key metrics. The primary catalyst was a disastrous Q2 earnings report: adjusted EPS of -$0.99 versus consensus of +$0.15, and revenue of $740.3M missing the $848.9M estimate.

Price target in focus: $60 per share — a level that would represent a new all-time high and roughly 33% upside from the latest closing price near $45. Strongest bullish factors: Robust revenue growth, a low P/E ratio of approximately 11, an asset-light B2B marketplace model, accelerating international expansion, and active share buybacks.

GigaCloud Technology (GCT) shares surged approximately 39% between early July and early August 2026, climbing from $33.21 to $46.23. Over the broader quarter, the stock followed a volatile path — falling sharply after its Q1 2026 earnings beat in early May, bottoming near $31.50 in June, then staging a powerful recovery.

VERX plunged -13.73% during regular trading on Tuesday, extending a pre-market decline of roughly -2% after the company's Q2 2026 results sparked a sharp selloff. The Q2 earnings and revenue beat consensus ($0.20 EPS vs. $0.19; $203.97M vs. $202.30M), but Q3 revenue guidance of $208M–$211M missed the $211.70M Street estimate, rattling investors.